Company Performance and Potential - Solventum, formerly 3M's Health Care division, has high-quality businesses that delivered consistent performance within 3M, but its separation has not lived up to potential, with current performance significantly lower than when it was part of 3M [2][3] - Solventum's shares are currently trading at $69, but Trian believes the company could be worth $140 by year-end 2027 if it restores performance to historical levels [1][12] - Solventum's profit margins have declined nearly unprecedentedly since the spin-off, with consensus estimates expecting a 425bps decline in its first full standalone year, making it a bottom decile performer [6][8] Historical Context and Spin-Off Analysis - Prior to the spin-off, 3M research analysts estimated Solventum would be valued at $33 billion, implying a share price more than double its current trading price [3] - Solventum was 3M's best-performing business, consistently the fastest-growing and highest-margin division, but as an independent company, it has struggled to maintain growth and margins [7] - The average mid-to-large cap spin delivered approximately +125bps and +160bps of margin expansion in the first and third full year following separation, while Solventum's margins have declined significantly [6][8] Strategic Recommendations - Solventum should focus on improving operating performance, portfolio actions, and prudent capital allocation to enhance value creation [1] - Simplifying Solventum's portfolio, particularly by addressing non-core segments like Dental Solutions, Health Info Systems, and Purification & Filtration, could improve focus and execution [10][12] - Divestitures of non-core businesses could accelerate deleveraging and enable value-enhancing capital allocation decisions, including dividends, share repurchases, and bolt-on M&A [12] Long-Range Plan and Shareholder Engagement - Trian has initiated dialogues with Solventum's management and board, urging the company to act with urgency to reverse declines and communicate a more ambitious Long-Range Plan (LRP) [4] - The LRP should aim to restore Solventum's performance to historical levels, with growth targets of 3% to 4% organically and EBIT margins of 26%-27%, similar to its performance within 3M [12] - Trian believes historical performance levels and spin-related opportunities should frame Solventum's operating targets and broader strategy [12]

Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategyAppointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmakerBOSTON, Jan. 8, 2025 /PRNewsw ...

ST. PAUL, Minn., Nov. 19, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that its executives will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 11:30 a.m. ET in New York, NY.A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of cre ...

Solventum (SOLV) recently launched the 3M Clarity precision grip attachments for the 3M Clarity aligners. These attachments, available exclusively with Clarity aligners, represent a significant advancement in aligner technology by addressing one of the longstanding challenges in clear aligner treatments — achieving durable, accurately shaped and stain-resistant attachments.With this development, Solventum aims to enhance treatment outcomes for orthodontic patients, offering both clinicians and patients a mo ...

Clarity Precision Grip Attachments are fully cured, pre-loaded and precisely resemble the digital treatment plan after bonding ST. PAUL, Minn., Nov. 14, 2024 /PRNewswire/ -- This month, Solventum (NYSE: SOLV), formerly 3M Health Care, officially launched an anticipated innovation in aligner treatment, 3M™ Clarity™ Precision Grip Attachments. Available exclusively with 3M™ Clarity™ Aligners, Clarity Precision Grip Attachments are designed to solve one of the biggest challenges with aligner treatment – creati ...

Solventum Corporation (NYSE:SOLV) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Kevin Moran - SVP, IR Bryan Hanson - CEO Wayde McMillan - CFO Conference Call Participants Travis Steed - Bank of America Patrick Wood - Morgan Stanley Vik Chopra - Wells Fargo David Roman - Goldman Sachs Rick Wise - Stifel Ryan Zimmerman - BTIG Jason Bednar - Piper Sandler Chris Senyek - Wolfe Research Operator Good afternoon. My name is Amy, and I will be your conference operator for today. ...

| --- | --- | --- | |---------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | © Solventum 2024. All rights reserved. Q3 FY24 earnings presentation November 7, 2024 | | | Forward-looking statements and use of document Forward-looking statements This presentation contains forward-looking information about Solventum's financial results and estimates and business prospects that involve substantial risks and uncertainties. In parti ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $.01 Per Share SOLV New York Stock Exchange Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☐ Emerging growth company ☐ Common Stock, $0.01 par value per share 172,754,070 shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PU ...

Solventum (SOLV) reported third-quarter 2024 adjusted earnings per share of $1.64, which beat the Zacks Consensus Estimate of $1.38 by 18.1%. The bottom line declined 42.9% year over year.GAAP EPS in the quarter was 70 cents, down 73.7% from the year-ago quarter’s level.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Revenue DetailsThe company reported revenues of $2.08 billion, up 0.4% reportedly from the prior-year recorded number. Organically, sales were up 0.3%. The metric beat ...

Exhibit 99.1 Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance • Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3% • GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS of $1.64 • Generated $169 million in cash from operations; free cash flow of $76 million • Raises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidance 1 1 ST. PAUL, Minn., November 7, 2024 /PRNewswire/ – Solventum (NYSE: SOLV) today reported financial re ...